Coordinated targeting of the EGFR signaling axis by MicroRNA-27a*

Oncotarget

Volumn 4, Issue 9, 2013, Pages 1388-1398

  Wu, Xiaoli ^a,b   Bhayani, Mihir K ^a   Dodge, Cristina T ^a   Nicoloso, Milena S ^a   Chen, Yunyun ^a   Yan, Xiaofeng ^a   Adachi, Makoto ^a   Thomas, Ligy ^b   Galer, Chad E ^c   Jiffar, Tilahun ^a   Pickering, Curtis R ^a   Kupferman, Michael E ^a   Myers, Jeffrey N ^a   Calin, George A ^a   Lai, Stephen Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AKT1; EGFR; miRNA; miRNA 27a*; miRNA 27a 5p; mTOR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 27A 3P; MICRORNA 27A 5P; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MOUSE; NONHUMAN; PROTEIN RNA BINDING; RNA SEQUENCE; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICRORNAS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884695742     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1239     Document Type: Article

References (51)

1. Cognetti DM, Weber RS and Lai SY. Head and neck cancer: an evolving treatment paradigm. Cancer. 2008; 113(7 Suppl):1911-1932.
2. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J CLin. 2010; 60(5):277-300.
3. Pulte D and Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15(9):994-1001.
4. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD and Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90(11):824-832.
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK and Milas L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002; 62(24):7350-7356.
6. Van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH and van Diest PJ. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. Journal of clinical pathology. 2006; 59(6):611-617.
7. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K and Park JO. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007; 109(8):1561-1569.
8. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, Cavalloni G, Torchio B, Mosso L, Chiorino G and Aglietta M. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer. 2011; 11:31.
9. Konecny GE, Santos L, Winterhoff B, Hatmal M, Keeney GL, Mariani A, Jones M, Neuper C, Thomas B, Muderspach L, Riehle D, Wang HJ, Dowdy S, Podratz KC and Press MF. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer. 2009; 100(1):89-95.
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-578.
11. Karamouzis MV, Grandis JR and Argiris A. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA. 2007; 298(1):70-82.
12. Karamouzis MV, Konstantinopoulos PA and Papavassiliou AG. Intriguing issues of EGFR targeting in head and neck cancer. Ann Oncol. 2007; 18(5):962.
13. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A and Baselga J. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007; 25(16):2171-2177.
14. Licitra L, Mesia R, Rivera F, Remenar E, Hitt R, Erfan J, Rottey S, Kawecki A, Zabolotnyy D, Benasso M, Storkel S, Senger S, Stroh C and Vermorken JB. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011; 22(5):1078-1087.
15. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005; 23(31):8081-8092.
16. Baselga J. Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients? Nature clinical practice Oncology. 2005; 2(6):284-285.
17. Fojo T and Parkinson DR. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much? Clin Cancer Res. 2010; 16(24):5972-5980.
18. Chen LF, Cohen EE and Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res. 2010; 16(9):2489-2495.
19. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-297.
20. Ambros V. The evolution of our thinking about microRNAs. Nat Med. 2008; 14(10):1036-1040.
21. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004.
22. Esquela-Kerscher A and Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-269.
23. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Jr., Haney J, Helfrich BA, Kato H, Hirsch FR and Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008;19(6):1053-1059.
24. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S and Purow B. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008; 68(10):3566-3572.
25. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD and Wu CW. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010; 70(21):8822-8831.
26. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma A, Kudoh S, Croce CM and Harris CC. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A. 2009; 106(29):12085-12090.
27. Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, Chen KC and Lai EC. Widespread regulatory activity of vertebrate microRNA* species. RNA. 2011; 17(2):312-326.
28. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M and Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature. 2005; 438(7068):685-689.
29. Li X and Carthew RW. A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell. 2005; 123(7):1267-1277.
30. La Vine DB, Coleman TA, Davis CH, Carbonell CE and Davis WB. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. Am J Clin Oncol. 2010; 33(3):217-220.
31. Machtay M, Moughan J, Trotti A, Garden AS, Weber RS, Cooper JS, Forastiere A and Ang KK. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26(21):3582-3589.
32. Guo L and Lu Z. The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? PLoS One. 2010; 5(6):e11387.
33. Filipowicz W, Bhattacharyya SN and Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008; 9(2):102-114.
34. Bhayani MK, Calin GA and Lai SY. Functional relevance of miRNA* sequences in human disease. Mutat Res. 2012; 731(1-2):14-19.
35. Okamura K, Phillips MD, Tyler DM, Duan H, Chou YT and Lai EC. The regulatory activity of microRNA* species has substantial influence on microRNA and 3' UTR evolution. Nat Struct Mol Biol. 2008; 15(4):354-363.
36. Ma Y, Yu S, Zhao W, Lu Z and Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett. 2010; 298(2):150-158.
37. Wang Q, Li DC, Li ZF, Liu CX, Xiao YM, Zhang B, Li XD, Zhao J, Chen LP, Xing XM, Tang SF, Lin YC, Lai YD, Yang P, Zeng JL, Xiao Q, et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. Oncogene. 2011.
38. Ghildiyal M, Xu J, Seitz H, Weng Z and Zamore PD. Sorting of Drosophila small silencing RNAs partitions microRNA* strands into the RNA interference pathway. RNA. 2010; 16(1):43-56.
39. Czech B and Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet. 2011; 12(1):19-31.
40. Iwasaki S, Kawamata T and Tomari Y. Drosophila argonaute1 and argonaute2 employ distinct mechanisms for translational repression. Molecular cell. 2009; 34(1):58-67.
41. Tay Y, Zhang J, Thomson AM, Lim B and Rigoutsos I. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008; 455(7216):1124-1128.
42. Bumcrot D, Manoharan M, Koteliansky V and Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nature chemical biology. 2006; 2(12):711-719.
43. Ozpolat B, Sood AK and Lopez-Berestein G. Nanomedicine based approaches for the delivery of siRNA in cancer. Journal of internal medicine. 2010; 267(1):44-53.
44. Landen CN, Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G and Sood AK. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005; 65(15):6910-6918.
45. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 2011; 19(6):1116-1122.
46. Pan GD, Yang JQ, Yan LN, Chu GP, Liu Q, Xiao Y and Yuan L. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World journal of gastroenterology: WJG. 2009; 15(4):431-440.
47. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y and Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res. 1997; 57(13):2681-2686.
48. Lai S, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL and Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005; 24(27):4442-4449.
49. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR and Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS medicine. 2005; 2(11):e313.
50. Hsieh AC, Bo R, Manola J, Vazquez F, Bare O, Khvorova A, Scaringe S and Sellers WR. A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens. Nucleic Acids Res. 2004; 32(3):893-901.
51. Vilella-Bach M, Nuzzi P, Fang Y and Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem. 1999; 274(7):4266-4272.